FP002 / FAPON - LARVOL DELTA

A Study to Investigate FP002 in Subjects With Advanced Malignancies (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Guangdong Fapon Biopharma Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Study to Investigate FP002 in Subjects With Advanced Malignancies (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Guangdong Fapon Biopharma Inc.

Metastases • New P1 trial • Oncology • Solid Tumor

Fapon Biopharma’s Anti-CD47 Antibody FP002 Earns IND Approval from FDA (PRNewswire) - "Fapon Biopharma, an innovative biotech company, announced today that its Investigational New Drug (IND) application of FP002, an anti-CD47 monoclonal antibody drug candidate, has been approved by FDA for clinical trials....Under this IND, the Company intends to initiate a single-armed, dose escalation and dose expansion study to investigate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) activity of FP002 in subjects with advanced malignancies. Apart from the FDA submission, it has also been submitted for IND application in China."

IND • New trial • Oncology